SPONSOR
Kriya Therapeutics, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Kriya Therapeutics, Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Trigeminal Neuralgia, Metabolic Dysfunction-associated Steatohepatitis (MASH).
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Kriya Therapeutics, Inc.
How many clinical trials has Kriya Therapeutics, Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Kriya Therapeutics, Inc., of which 2 are actively recruiting participants. These trials cover conditions including Trigeminal Neuralgia, Metabolic Dysfunction-associated Steatohepatitis (MASH). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Kriya Therapeutics, Inc. research focus on?
Kriya Therapeutics, Inc. clinical trials span Trigeminal Neuralgia, Metabolic Dysfunction-associated Steatohepatitis (MASH). The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Kriya Therapeutics, Inc. clinical trial?
To participate in a Kriya Therapeutics, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Kriya Therapeutics, Inc. trials with current recruitment status updated daily.
Clinical Trials by Kriya Therapeutics, Inc.
NCT07596485 Phase 1, Phase 2
Recruiting
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
Trigeminal Neuralgia
NCT07732400 Phase 1, Phase 2
Recruiting
A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatohepatitis (MASH)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology